A novel peptide-IgG conjugate, CAP18106-138-IgG, that binds and neutralizes endotoxin and kills gram-negative bacteria

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 621-632

  Fletcher, Mark A ^b   Kloczewiak, Marek A ^d   Loiselle, Paul M ^d   Ogata, Masanori ^c   Vermeulen, Mary W ^d   Zanzot, Emily M ^d   Warren, H Shaw ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Pasteur Merieux Connaught   (France)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; IMMUNOGLOBULIN G; PEPTIDE;

ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; BACTERICIDAL ACTIVITY; CONJUGATION; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE INFECTION; IMMUNOMODULATION; KLEBSIELLA PNEUMONIAE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SALMONELLA MINNESOTA; SEPSIS; STAPHYLOCOCCUS AUREUS;

EID: 0031016875     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.621     Document Type: Article

References (7)

1. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
2. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097-102.
3. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1006.
4. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
5. Lindberg AA, Greisman SE, Svenson SB. Induction of endotoxin tolerance with nonpyrogenic O-antigenic oligosaccharide-protein conjugates. Infect Immun 1983;41:888-95.
6. Greisman SE, Young EJ, DuBuy JB. Mechanisms of endotoxin tolerance. VIII. Specificity of serum transfer. J Immunol 1973;111:1349-60.
7. Tate WJ, Douglas HL, Braude AI. Protection against lethality of E. coli endotoxins with "O" antiserum. Ann NY Acad Sci 1966;133:746-62.